Drug Information

Drug General Information
Drug ID
D0C1LH
Former ID
DIB010630
Drug Name
DS-8273
Drug Type
Antibody
Indication Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] Phase 1 [524661]
Company
Daiichi sankyo
Target and Pathway
Target(s) D(1B) dopamine receptor Target Info [550586]
KEGG Pathway Calcium signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Dopaminergic synapse
PANTHER Pathway Dopamine receptor mediated signaling pathway
Reactome Dopamine receptors
G alpha (s) signalling events
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
GPCR ligand binding
GPCR downstream signaling
References
Ref 524661ClinicalTrials.gov (NCT02076451) Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas. U.S. National Institutes of Health.
Ref 550586Clinical pipeline report, company report or official report of Daiichi Sankyo.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.